



ORGANISED BY:



MALAYSIAN  
SOCIETY OF  
NEPHROLOGY

ENDORSED BY:



38<sup>th</sup>

# ANNUAL CONGRESS OF MALAYSIAN SOCIETY OF NEPHROLOGY

BREAKING BOUNDARIES IN NEPHROLOGY

26-28 JULY 2024

KUALA LUMPUR CONVENTION CENTER (KLCC)

## PROGRAMME BOOK

### Gold Sponsors

GSK



### Silver Sponsors

AstraZeneca

Baxter

Boehringer  
Ingelheim



FRESENIUS  
MEDICAL CARE

### Bronze Sponsors

AIN MEDICARE

KYOWA KIRIN

Pfizer

### Sponsors

Abbott

AIM MEDICAL  
SUPPLIES

Dr.Reddy's

Davita

FRESENIUS  
KABI

hovid  
Continuous Innovation & Quality



NOVARTIS

novugen

Otsuka

VIATRIS

VITAL

MEGA We care

NIPRO

Roche

<https://msncongress.com/>



# CONTENTS

<b>Welcome Message from Organising Chair and Scientific Chair</b>	<b>1</b>
<b>Organising Committee</b>	<b>2</b>
<b>Programme at a Glance</b>	<b>3-8</b>
<b>International Speakers</b>	<b>9</b>
<b>Local Speakers</b>	<b>10-12</b>
<b>Advertisements</b>	<b>13-24</b>



# WELCOME MESSAGE FROM ORGANISING CHAIR AND SCIENTIFIC CHAIR



## Welcome to MSN Congress 2024

Dear Colleagues and Friends,

It is with great honor and pleasure to welcome you to the 38th Annual Congress of Malaysian Society of Nephrology (MSN) 2024 in the state-of-the-art Kuala Lumpur Convention Center. To our foreign colleagues, welcome to Malaysia!

The theme “Breaking Boundaries in Nephrology” is set to unravel a tapestry of ground breaking topics that pushes the boundaries of conventional nephrology and address areas that remains a challenge in kidney care. In this 2.5 days congress, we have received the highest record of 196 abstracts submissions (including 27 international abstracts), with over 1,000 total registered delegates and 32 industry sponsors. We also have the privileged of having 10 distinguished international faculties and 45 local faculties to share their expertise during this congress.

This year, besides the scientific programme, for the first time we have introduced the MSN Ignite stage with insightful presentation during the coffee breaks in the exhibition hall. Please find your way and take this opportunity to listen to this session during the refreshment! Also please join us for the oral and e-poster free paper presentation, NRR training session that has been lined up.

The year 2024 marks a very special year for MSN as it celebrates its 40th anniversary since its founding in 1984. For the past 40 years, MSN has made impressive milestones and contributions led by the various MSN presidents. Let's celebrate our past achievement together, renew friendships and extend our network with each other.

We hope that you will enjoy the program that we have prepared for you. Happy 40th birthday MSN!

Sincerely yours,

**Dato' Dr Lily Mushahar**  
**Congress Chair**  
**MSN President 2022-2024**

**Dr Fariz Safhan Mohamad Nor**  
**Scientific Chair**  
**MSN Council 2022-2024**





# ORGANISING COMMITTEE

**Congress Chair: DATO' DR LILY MUSHAHAR**

**Congress Co-Chair: PROF DR LIM SOO KUN**

**Scientific Chair: DR FARIZ SAFHAN MOHAMAD NOR**

**Scientific Co-Chair: ASSOC. PROF DR NOR FADHLINA BINTI ZAKARIA**

**Scientific Committee: ASSOC. PROF DR WAN AHMAD HAFIZ BIN WAN MD ADNAN**

**Scientific Committee: DR THONG KAH MEAN**

**Secretary: ASSOC. PROF DR RUSLINDA BINTI MUSTAFAR**

**Treasurer: DR ESTHER TAN ZHAO ZHI**

**Sponsorship & Exhibition: DR MORRIS WO CHEE YUEN**

**Sponsorship & Exhibition: PROF DR ABDUL HALIM BIN ABDUL GAFOR**

**Social Programme & Publicity: DR WAN ZUL HAIKAL HAFIZ BIN WAN ZUKIMAN**

**Social Programme & Publicity: DR WAN HAZLINA WAN MOHAMAD**

**Publication & Abstract: PROF DR CHRISTOPHER LIM THIAM SEONG**

**Publication & Abstract: DR SELVA KUMAR A/L SIVAPUNNIAM**





# PROGRAMME

# DAY 1

Programme Theme: Breaking Boundaries in Nephrology			
DAY 1 (26 July 2024) Friday			
0700-1700	Registration (Level 3 Centre Core Registration Counter)		
	Grand Ballroom		
	NRR Presentation		
0800-0945	Chair: NRR team - Kah Mean THONG & Sunita BAVANANDAN Lai Seong HOOI / Sunita BAVANANDAN / NRR team		
0945-1015	Opening Ceremony		
	COFFEE BREAK (Banquet Hall)		
	MSN Ignite (PFIZER)		
1015-1100	ABC of Pneumococcal Infections and Vaccination in Patients with CKD Rosnawati YAHYA		
	Grand Ballroom	Conference Hall 2	Conference Hall 1
	State of the Art Symposium 1 Cardio Renal Metabolic Continuum	CME 1 ESKD - related Issues	General Nephrology 1 Glomerular Disease 1
1100-1215	Chair: Chong Men LEONG & Lydia KAMARUZAMAN	Chair: Ruslinda MUSTAFAR & Wan Zul Haikal Hafiz WAN ZUKIMAN	Chair: Wan Hazlina WAN MOHAMAD & Chen Au PEH
1100-1120	Gaining Weight but Losing the Kidney Rohana ABDUL GHANI	Hepatitis C: Addressing the Unmet Needs Rosmawati MOHAMED	Proteinuria in Children and Adolescent Selva Kumar SIVAPUNNIAM
1120-1140	The Cardio - Kidney - Metabolic Syndrome in CKD Care Sydney TANG	CKD - MBD: Never Ending Challenges! Fariz Safhan MOHAMAD NOR	Managing Complications of Nephrotic Syndrome Christopher Thiam Seong LIM
1140-1200	Addressing Diabetes Care in CKD Treatment Gaps Bak Leong GOH	Nutritional Management in Dialysis Patients Zulfitri Azuan MAT DAUD	KDIGO 2024 Lupus Nephritis - What is New? Kah Mean THONG
1200-1215	Q & A	Q & A	Q & A
	Lunch Symposium 1 ASTRAZENECA	Lunch Symposium 2 BAYER	Lunch Symposium 3 BOEHRINGER INGELHEIM
	'The PAST': Historical Treatment Options for Hyperkalaemia Management and Unmet Needs Azmee MOHD GHAZI	Finerenone: Spotlighting a Pillar in Managing Residual Risk for Chronic Kidney Disease in Type 2 Diabetes Sydney TANG, Soo Kun LIM	Riding the Renal Wave - Breakthrough in Early CKD Shiong Shiong YEW
1215-1315	'The PRESENT And The FUTURE: LOKELMA – Avant - Garde of Hyperkalaemia Management Vijaya B RAMASAMY		Reclaiming Time - Implication of CKD on Healthcare See Cheng YEO
1315-1415	Friday Prayer		





# PROGRAMME

# DAY 1

	Grand Ballroom		
1415-1500	<b>Plenary 1:</b> <b>Breaking Boundaries in Nephrology Using Sustainable Green Technologies</b> Chair: Lily MUSHAHAR Vivekanand JHA		
1500-1545	<b>COFFEE BREAK (Banquet Hall)</b> <b>MSN Ignite (ASTRAZENECA)</b> <b>Complement Dysregulation in aHUS: From Diagnosis to Management</b> Karmila ABU BAKAR		
	Grand Ballroom	Conference Hall 2	Conference Hall 1
1545-1700	<b>State of the Art Symposium 2</b> <b>Glomerular Disease 2</b> Chair: Rosnawati YAHYA & Kah Mean THONG	<b>CME 2</b> <b>Innovations Transforming</b> <b>Dialysis Care</b> Chair: Yusuf ABU SHAMSI & Anim MD SHAH	<b>General Nephrology 2</b> <b>Interventional Nephrology /</b> <b>POCUS</b> Chair: Wan Hazlina WAN MOHAMAD & Vinoth Kasi Rajan ATHMALINGAM
1545-1605	<b>Advances in Treatment of IgA</b> <b>Nephropathy</b> Adrian LIEW	<b>Vaccinations for Dialysis</b> <b>Patients</b> Wan Ahmad Hafiz WAN MD ADNAN	<b>Dialysis Catheter Dysfunction -</b> <b>What Would an Interventional</b> <b>Nephrologist Do?</b> Wan Zul Haikal Hafiz WAN ZUKIMAN
1605-1625	<b>Personalised Treatment of</b> <b>Anti - PLA2R Membranous</b> <b>Glomerulonephritis</b> Vivekanand JHA	<b>Dialysis Centre - From</b> <b>Machinery to Greenery</b> Eason CHANG	<b>The 5th Pillar of Clinical</b> <b>Examination - Insonation in</b> <b>Nephrology Practice</b> Suryati YAKOB
1625-1645	<b>Role of Plasma Exchanges in</b> <b>Glomerulonephritis</b> Soo Kun LIM	<b>Haemodiafiltration - Is It Ready</b> <b>for the Main Stage?</b> Peter KOTANKO	<b>Creation of AVF in Patients with</b> <b>"No Suitable Veins" and</b> <b>Paediatric Groups</b> Angamuthu RAJOO
1645-1700	Q&A	Q&A	Q &A
1700-1800	<b>Tea Symposium 1</b> <b>ABBOTT</b> <b>Hypertension: Striking the</b> <b>right balance between BP</b> <b>reduction and protection</b> Eng Khim NG		
1800 - 2100	<b>FACULTY DINNER (By Invitation)</b> Venue: FOOK KL by Samadhi		





# PROGRAMME

# DAY 2

DAY 2 (27 July 2024) Saturday			
0700-1700	Registration (Level 3 Centre Core Registration Counter)		
	Grand Ballroom		
0800-0845	Plenary 2: Chair: Fariz Safhan MOHAMAD NOR <b>Artificial Intelligence in Kidney Care or Health Care</b> Peter KOTANKO		
0845-0930	Plenary 3: Chair: Fariz Safhan MOHAMAD NOR <b>CKD Care: Promising Advancement in the New Era</b> Sunita BAVANANDAN		
0930-1015	<b>COFFEE BREAK (Banquet Hall)</b> <b>MSN Ignite (BAXTER)</b> <b>If I can, YOU CAN! - A true story from home dialysis patient</b> Raihana ROSMAN  <b>"Personalized PD care in the modern world"</b> Alexander Kok Yip CHOW		
	Grand Ballroom	Conference Hall 2	Conference Hall 1
1015-1130 Concurrent NRR Workshop*	<b>State of the Art Symposium 3</b> <b>Insights on Kidney Transplant</b> Chair: Esther Zhao Zhi TAN & Lydia KAMARUZAMAN	<b>CME 3</b> <b>Critical Care Nephrology</b> Chair: Fariz Safhan MOHAMAD NOR & Soo Kun LIM	<b>General Nephrology 3</b> <b>Conservative Non-Dialysis Care</b> Chair: Rashidi SAIDIN & Christopher Thiam Seong LIM
1015-1035	<b>Precision Medicine in Donor - Recipient Compatibility Evaluation</b> Maisarah JALALONMUHALI	<b>Fluid Dynamic in Critical Care Settings</b> Nurul Zaynah NORDIN	<b>Non-Dialysis Care: Who Needs It and How?</b> Nor Fadhlina ZAKARIA
1035-1055	<b>Antibody - Mediated Rejection: Can We Do Better?</b> Rosnawati YAHYA	<b>The Evolution of Kidney Replacement Therapy in Critical Care</b> Ruslinda MUSTAFAR	<b>Addressing Non - Physical Symptoms in Advanced Chronic Kidney Disease</b> Benjamin Wei Wang TAN
1055-1115	<b>Approach to Latent TB in Transplant Recipient</b> Mohamad Zaimi ABDUL WAHAB	<b>Understanding Nutrients and Micronutrients Loss During CKRT</b> Nuttha LUMLERTGUL	<b>Bridging the Gap Between Renal Palliative Care: Evidence and Clinical Application</b> Rafidah ABDULLAH
1115-1130	Q&A	Q&A	Q&A
1130-1300	<b>Oral/Poster Presentation 1</b> Poster Presentation (Poster Kiosk)	<b>Oral/Poster Presentation 2</b> Poster Presentation (Poster Kiosk)	<b>Oral/Poster Presentation 3</b> Poster Presentation (Poster Kiosk)





# PROGRAMME

# DAY 2

	Grand Ballroom	Conference Hall 2	Conference Hall 1
300-1400	<b>Lunch Symposium 4</b> <b>NOVO NORDISK</b> <b>Flowing with Semaglutide in CKD – The New Pillar on The Block</b> Vijaya B RAMASAMY  <b>The Balancing Act between 2 Hs'</b> Yok Wai CHOW	<b>Lunch Symposium 5</b> <b>ASTRAZENECA</b> <b>Weathering the CKD Storm: Expert Strategies in Managing CKD &amp; its Complexities.</b> Kenneth Koah Kien LAI	<b>Lunch Symposium 6</b> <b>NOVARTIS</b> <b>HF &amp; CKD: A Wake Up Call in Cardiorenal Syndrome The Heart Failure and Renal Conundrum</b> Wan Azman WAN AHMAD  <b>Case Discussion: Protecting the Kidneys in the Face of Improving HF Outcomes</b> Wan Ahmad Hafiz WAN MD ADNAN
1400-1515 Concurrent NRR Workshop**	<b>State of the Art Symposium 4</b> <b>Peritoneal Dialysis</b> Chair: Benjamin Wei Wang TAN & Maisarah JALALONMUHALI	<b>CME 4</b> <b>Common Challenges in Day - to - Day Haemodialysis Care</b> Chair: Wan Ahmad Hafiz WAN MD ADNAN & Chong Men LEONG	<b>General Nephrology 4</b> <b>The Young Nephrologists as Our Future Leaders</b> Chair: Chek Loong LOH
1400-1420	<b>Adapting the Peritoneal Dialysis Prescription to the Individual Patient</b> Lily MUSHAHAR	<b>Common But Confusing - Blood Pressure Management</b> Nor Fadhlin ZAKARIA	<b>Key Concepts of Leadership in Nephrology</b> Zaki Morad MOHAMAD ZAHER
1420-1440	<b>Fluid Control in PD patients</b> Yi-Wen CHIU	<b>Common But Difficult to Tackle - Prevention &amp; Treatment of Catheter Infection</b> Rashidi SAIDIN	<b>Forum: Challenges and Struggles of Nephrologists Working in Different Regions in Malaysia</b> <b>Moderator:</b> Chek Loong LOH <b>Panellists:</b> Lydia KAMARUZAMAN, Wan Syamir Zharif WAN AHMAD KAMMAL, Vinoth Kasi Rajan ATHMALINGAM
1440-1500	<b>Reducing Infection Rates on PD</b> Esther Zhao Zhi TAN	<b>Common But Not Achievable - Optimising Anaemia Management</b> Paweena SUSANTITAPHONG	
1500-1515	Q&A	Q&A	Q&A
<b>Grand Ballroom</b>			
1515-1600	<b>COFFEE BREAK (Banquet Hall)</b> <b>MSN Ignite (BAYER)</b> <b>Meet the Expert: Finerenone as a Pillar in Addressing Residual Risk in Chronic Kidney Disease and Type 2 Diabetes</b> Sydney TANG		





# PROGRAMME

# DAY 2

	Grand Ballroom	Conference Hall 2	Conference Hall 1
1600-1715	<b>State of the Art Symposium 5</b> <b>Regional Society</b> Chair: Soo Kun LIM & Nor Fadhlin ZAKARIA	<b>CME 5</b> <b>Patient &amp; Carer Empowerment</b> Chair: Selva Kumar SIVAPUNNIAM & Rafidah ABDULLAH	<b>General Nephrology 5</b> <b>Urology (MSN-MUA)</b> Chair: Morris Chee Yuen WO & Wan Zul Haikal Hafiz WAN ZUKIMAN
1600-1620	<b>Home Hemodialysis as A Promising Alternative in ANZ</b> Yvonne SHEN	<b>Empowerment: Exploring Patients Behavior Dynamics</b> Hariyati Shahrima ABDUL MAJID	<b>Approach to Complicated UTI</b> Chong Men LEONG
1620-1640	<b>Dietary Lifestyle Changes Policy in Thailand</b> Surasak KANTACHUVESIRI	<b>Patients' Expectation in Kidney Care</b> Khairul Shazwali TAIB	<b>Obstructive Uropathy Across The Ages</b> Syahril Anuar SALAUDDIN
1640-1700	<b>A Structured CKD Care in Taiwan</b> Yi-Wen CHIU	<b>Pre-dialysis Education</b> Fatimah Hasanah MOHD RADZI	<b>Kidney Cysts and Its Significance</b> Shanggar KUPPUSAMY
1700-1715	Q&A	Q&A	Q&A
1715-1815	<b>Tea Symposium 2</b> <b>ROCHE</b> <b>Overlooking Issues in Pre-Dialysis Treatment Perspective</b> Paweena SUSANTITAPHONG  <b>Integrating Holistic Approaches in Renal Palliative Care</b> Rafidah ABDULLAH		
1815-2000	<b>Conference Hall 1</b> <b>MSN AGM</b>		





# PROGRAMME

# DAY 3

## DAY 3 (28 July 2024) Sunday

### Grand Ballroom

#### Plenary 4

Chair: Ruslinda MUSTAFAR

Using Technologies for Optimisation in Kidney Care

Chia-Te LIAO

#### Debate

Chair: Esther Zhao Zhi TAN / Rashidi SAIDIN

Telemedicine is Beneficial for Our Future Nephrology Services

Alexander Kok Yip CHOW (propose)

Yudisthra M GANESHADEVA (oppose)

#### COFFEE BREAK (Banquet Hall)

#### MSN Ignite (NIPRO)

Expanded Hemodialysis (HDx): Dialysis in Evolution

Behram Ali KHAN

#### State of the Art Symposium 6

#### Advances in Kidney Care

Chair: Wan Ahmad Hafiz WAN MD ADNAN & Rafidah ABDULLAH

#### The Role of Genetic Testing in Kidney Care

Sok Kun TAE

#### Renal Denervation in Controlling Difficult Hypertension

Wan Azman WAN AHMAD

#### Remote Patient Monitoring: How It Benefits Patients

Wan Hazlina WAN MOHAMAD

#### Q&A

#### Awards & Closing Ceremony

#### Lunch



# INTERNATIONAL SPEAKERS



**Adrian LIEW**

Mount Elizabeth Novena Hospital,  
Singapore



**Chia-Te LIAO**

Taipei Medical University,  
Taiwan



**Nuttha LUMLERTGUL**

King Chulalongkorn  
Memorial Hospital,  
Thailand



**Paweena SUSANTITAPHONG**

Chulalongkorn University,  
Thailand



**Peter KOTANKO**

Renal Research Institute,  
USA



**Sydney TANG**

The University of Hong Kong,  
Hong Kong



**Surasak KANTACHUVESIRI**

Faculty of Medicine,  
Ramathibodi Hospital, Bangkok,  
Thailand



**Vivekanand JHA**

The George Institute for  
Global Health,  
India



**Yi-Wen CHIU**

Kaohsiung Medical University,  
Taiwan



**Yvonne SHEN**

Royal North Shore Hospital  
Sydney University,  
Australia





# LOCAL SPEAKERS



**Alexander Kok Yip CHOW**  
 Hospital Raja Permaisuri Bainun,  
 Ipoh, Malaysia



**Angamuthu RAJOO**  
 Anga Plastic & Cosmetic Surgery,  
 Johor Bahru



**Bak Leong GOH**  
 Ministry of Health Malaysia



**Benjamin Wei Wang TAN**  
 Nephrologist



**Chek Loong LOH**  
 Hospital Raja Permaisuri Bainun,  
 Ipoh, Malaysia



**Chong Men LEONG**  
 Sunway Medical Centre Penang,  
 Malaysia



**Christopher Thiam Seong LIM**  
 Universiti Putra Malaysia



**Eason CHANG**  
 Pantai Hospital Laguna Merbok



**Esther Zhao Zhi TAN**  
 Selayang Hospital



**Fariz Safhan MOHAMAD NOR**  
 Hospital Tengku Ampuan Afzan,  
 Kuantan



**Fatimah Hasanah**  
**MOHD RADZI**  
 CKD Clinical Nurse



**Hariyati Shahrima ABDUL MAJID**  
 IJN College



**Kah Mean THONG**  
 Hospital Raja Permaisuri Bainun,  
 Ipoh



**Khairul Syazwali TAIB**  
 Technical Delivery & Operations,  
 Upstream Consulting Firm,  
 Malaysia



**Lai Seong HOOI**  
 National Renal Registry,  
 Malaysia



**Lily MUSAHAR**  
 Hospital Tuanku Jaafar Seremban,  
 Negeri Sembilan





# LOCAL SPEAKERS



**Lydia KAMARUZAMAN**  
Universiti Kebangsaan Malaysia,  
Malaysia



**Maisarah JALALNMUHALI**  
University of Malaya,  
Malaysia



**Mohamad Zaimi  
ABDUL WAHAB**  
Hospital Kuala Lumpur, Malaysia



**Nor Fadhlin ZAKARIA**  
Universiti Putra Malaysia,  
Malaysia



**Nurul Zaynah NORDIN**  
Hospital Kuala Lumpur,  
Malaysia



**Philip N. JEREMIAH**  
KPJ Ampang Puteri Specialist  
Hospital, Malaysia



**Rafidah ABDULLAH**  
Hospital Putrajaya, Malaysia



**Rashidi SAIDIN**  
Avisena Specialist Hospital,  
Shah Alam, Malaysia



**Rohana ABDUL GHANI**  
Universiti Teknologi MARA (UiTM),  
Malaysia



**Rosmawati MOHAMED**  
University Malaya Medical Centre,  
Malaysia



**Rosnawati YAHYA**  
Sunway Medical Centre,  
Malaysia



**Ruslinda MUSTAFAR**  
Universiti Kebangsaan Malaysia,  
Malaysia



**Selva Kumar SIVAPUNNIAM**  
Hospital Selayang,  
Malaysia



**Shahnaz Shah FIRDAUS KHAN**  
Hospital Tengku Ampuan Rahimah  
Klang, Malaysia



**Shanggar KUPPUSAMY**  
Department of Surgery,  
Universiti Malaya,  
Malaysia



**Sok Kun TAE**  
University Malaya, Malaysia





# LOCAL SPEAKERS



**Soo Kun LIM**  
University Malaya Medical Centre,  
Malaysia



**Sunita BAVANANDAN**  
Hospital Kuala Lumpur,  
Malaysia



**Suryati YAKOB**  
Hospital Kuala Lumpur,  
Malaysia



**Syahril Anuar SALAUDDIN**  
Hospital Tengku Ampuan Afzan  
(HTAA), Kuantan, Malaysia



**Vinoth Kasi Rajan  
ATHMALINGAM**  
Queen Elizabeth Hospital,  
Malaysia



**Wan Ahmad Hafiz WAN  
MD ADNAN**  
Universiti Malaya Medical Centre,  
Malaysia



**Wan Azman WAN AHMAD**  
University Malaya Medical Centre,  
Malaysia



**Wan Hazlina WAN MOHAMAD**  
Hospital Kuala Lumpur,  
Malaysia



**Wan Syamir Wan Zharif  
WAN AHMAD KAMMAL**  
Hospital Tuanku Fauziah,  
Malaysia



**Wan Zul Haikal Hafiz  
WAN ZUKIMAN**  
Hospital Sultan Abdul Aziz Shah,  
Malaysia



**Yudisthra M  
GANESHADEVA**  
KPJ Johor Specialist Hospital,  
Malaysia



**Zaki Morad MOHAMAD ZAHER**  
KPJ Ampang Puteri Specialist Hospital,  
Malaysia



**Zulfetri Azuan MAT DAUD**  
Universiti Putra Malaysia,  
Malaysia





# IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN'T YOU?<sup>1</sup>



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

**NOW APPROVED  
IN MALAYSIA**

YOU CAN NOW PROTECT YOUR PATIENTS  
WITH SHINGRIX.

#### INDICATIONS

Shingrix is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in

**≥50**

Adults 50 years of age or older<sup>1</sup>

**≥18**

Adults 18 years of age or older at increased risk of HZ<sup>1</sup>



**CDC recommends vaccinating your patients** ≥ 50 years with 2 doses of SHINGRIX.<sup>2</sup>



**Protection that lasts. SHINGRIX offers 97% efficacy** to adults ≥ 50 years, and 91% to adults ≥ 70 years.<sup>1\*</sup>



**Established safety profile.** Most vaccination reactions were **mild to moderate, with a median duration of 2 - 3 days.**<sup>3†</sup>

**VACCINATE NOW FOR PROTECTION THAT LASTS<sup>1</sup>**

Median follow-up period of 3.1-4 years in ZOE-50/70.<sup>1</sup>

\* 97.2% (95% CI: 93.7; 99.0) VE against confirmed shingles in subjects ≥ 50 years in ZOE-50, 91.3 (95% CI: 86.8; 94.5) VE against confirmed shingles in subjects ≥ 70 years in pooled data from ZOE-50 and ZOE-70.<sup>1</sup>

† Median duration of 3 days or less for local symptoms and 2 days or less for general symptoms.<sup>3</sup>

**References:** 1. Shingrix Prescribing Information. 2. Centers for Disease Control and Prevention. Shingles vaccination. Reviewed May 8, 2023. Accessed May 8, 2024. <https://www.cdc.gov/vaccines/vpd/shingles/public/Shingrix/index.html>. 3. López-Fauqued M, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. *Vaccine*. 2019;37:2482-93.

For Malaysia Healthcare Professionals

Adverse events should be reported to [drugsafetyinfo.my@gsk.com](mailto:drugsafetyinfo.my@gsk.com)

Trade marks are owned by or licensed to the GSK group of companies. © 2024 GSK group of companies or its licensors.

GlaxoSmithKline Pharmaceutical Sdn Bhd 195801000141 (3277-U)  
HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama,  
Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia.  
Tel: (603) 2037 9808 [www.my.gsk.com](http://www.my.gsk.com)

PM-MY-SGX-LBND-240005 06/24



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code.

For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at [medinfo.my@gsk.com](mailto:medinfo.my@gsk.com).





Now Available

**RYBELSUS®**  
semaglutide tablets

# FIRST and Only Oral GLP-1RA<sup>1</sup>

## For Holistic Diabetes Management<sup>2</sup>

**75%  
GREATER\***

HbA<sub>1c</sub> REDUCTION VS  
SITAGLIPTIN<sup>3,†,a</sup>

**55%  
GREATER\***

HbA<sub>1c</sub> REDUCTION VS  
EMPAGLIFLOZIN<sup>4,†,b</sup>

**UP TO  
5 KG  
WEIGHT  
REDUCTION<sup>5,†,c</sup>**

**WAIST  
CIRCUMFERENCE  
-4.5cm<sup>5,†,c</sup>**

a: Results are from a 26-week, randomised, double-blind, active-controlled trial in 1864 adult patients with type 2 diabetes.<sup>1,3</sup> Patients achieved -1.4% HbA<sub>1c</sub> reduction with RYBELSUS® 14 mg (Baseline: 8.3%, n=465, \*P<0.001) vs -0.8% with sitagliptin 100 mg (Baseline: 8.3%, n=467).<sup>1,3</sup>  
b: Results are from a 26-week, randomised, open-label, active-controlled trial in 822 adult patients with type 2 diabetes.<sup>1,4</sup> Patients achieved -1.4% HbA<sub>1c</sub> reduction with RYBELSUS® 14 mg (Baseline: 8.1%, n=411, \*P<0.001) vs -0.9% with empagliflozin 25 mg (Baseline: 8.1%, n=410).<sup>1,4</sup>  
c: Results are from a 52-week, randomised, double-blind, double-dummy trial.<sup>1,5</sup> Rybelsus® 14 mg (Baseline 92.9 kg, n=285) \*P<0.05 vs -3.1 kg with liraglutide 1.8 mg (Baseline 95.5 kg, n=284) vs -1.0 kg with placebo (Baseline 93.2 kg, n=142).<sup>1,5</sup>

† Trial Product Estimand.

\* Open in Google Docs

### References:

1. RYBELSUS® Malaysia Prescribing Information. 2. Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Sep 24:1-42. 3. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide versus sitagliptin in patients with type 2 diabetes uncontrolled with metformin alone or with sulphonylurea: the PIONEER 3 randomised clinical trial. JAMA. 2019;321(15):1466-1480. 4. Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272-2281. 5. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019; 394(10192):39-50.



Rybelsus®  
Full Prescribing  
Information



To Know More,  
Scan Here!\*



Novo Nordisk Pharma (M) Sdn Bhd Registration No. 199201009267 (240770-W)  
Menara 1 Sentrum, Level 16, No. 201, Jalan Tun Sambanthan, 50470 Kuala Lumpur, Malaysia.  
Tel: +603 2265 7300 Fax: +603 2276 5161 www.novonordisk.com

MY23RYB00200  
For healthcare professional use only.  
2024 © Novo Nordisk Pharma (Malaysia) Sdn. Bhd.

**RYBELSUS®**  
semaglutide tablets



# Patients with T2D can begin Ryzodeg® at any stage of their insulin journey<sup>1,2</sup>

Ryzodeg®: A flexible dosing regimen that can keep patients on the road to treatment success<sup>2</sup>



**ARISE confirms initiating or switching to Ryzodeg® improves glycaemic control with significantly low rates of hypoglycaemia.<sup>2-5</sup>**



Patients from all prior treatment groups experienced the freedom of significant reductions in HbA<sub>1c</sub>.<sup>3</sup>




Adapted from Fulcher GR et al. 2022<sup>3</sup>  
 \*95% CI, p < 0.0001

In addition to significant reductions in HbA<sub>1c</sub>, Ryzodeg® delivered significant reduction in the rate of:



([95% CI 0.30; 0.71]; P = 0.0004)



([95% CI 0.12; 0.43]; P < 0.0001)

**and reduction in severe hypoglycaemia after initiating or switching to Ryzodeg®.**

Adapted from Fulcher GR et al. 2022<sup>3</sup>

**References:** 1. Chan SP, et al. Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia. Malays Fam Physician. 2023 May 4;18:31. 2. Ryzodeg® Malaysia Prescribing Information. 3. Fulcher GR, et al. Initiating or switching to insulin degludec/insulin aspart in adults with Type 2 Diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022; 39: 3735-3748. 4. Kumar A, et al. Clinical use of the co-formulation of insulin degludec and insulin aspart. Int J Clin Pract. 2016;70(8):657-667. 5. Phillis-Tsimikas A, et al. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019; 147:157-165.

**Scan the QR code for Ryzodeg® Abbreviated Prescribing Information (API) and Full Prescribing Information (PI).**

Downloadable copies of API and PI are available upon request. Please contact Novo Nordisk Sales Representative for assistance. The claims/information in this materials is based on the approved PI on date of print. Scan the QR code for the latest API and PI.



**Novo Nordisk Pharma (Malaysia) Sdn Bhd** (240770W)  
 Menara 1 Sentrum, Level 16, No. 201, Jalan Tun Sambanthan,  
 50470 Kuala Lumpur, Malaysia.  
 Tel: +603 2265 7300 Fax: +603 2276 5161 [www.novonordisk.com](http://www.novonordisk.com)

**For healthcare professionals only.**  
 2024 © Novo Nordisk Pharma (Malaysia) Sdn. Bhd.  
 MY24R2G00064







 **LOKELMA™**  
powder for oral suspension  
Sodium zirconium cyclosilicate

LOKELMA™ is indicated for the treatment of Hyperkalaemia in adult patients.<sup>1</sup>

**THE NEW INNOVATIVE K<sup>+</sup> BINDER**  
**UNIQUE | RAPID | SUSTAINED<sup>1-4</sup>**

**NOW AVAILABLE IN MALAYSIA**

AstraZeneca 

At UPMC, we are dedicated to providing patients and the public with essential information on the prevention, comprehensive treatment, and palliative care of kidney-related illnesses.

### Referral Process:

- Walk-in: Visit the UPMC facility directly for immediate assistance.
- Patient Portal: Use the UPMC Patient Portal for easy online referrals.
- Email: Contact us via the provided email for referrals and inquiries.



## UPM CARING (UPMC)



CONTACT US

Hospital Sultan Abdul Aziz Shah  
Universiti Putra Malaysia  
03 9769 5500

[hsaas.contact@upm.edu.my](mailto:hsaas.contact@upm.edu.my)  
<https://patient.hsaas.upm.edu.my>

## HOW CAN WE HELP YOU?

### Dialysis

Tailoring Kidney Replacement Therapy to Fit Your Lifestyle

### Sponsor

Sponsorships Secured, Lives Restored:  
Supporting Kidney Replacement Therapy Together

### Quality of Life

Patients First: Ensuring Every Decision Enhances Quality of Life through Shared Decision-Making

### Lifestyle


Revitalize Your Life: Embrace a Healthier You





In adult patients with CKD associated with T2D

## 3 pillars of drug therapy should be considered to help reduce CV risk and slow CKD progression<sup>1</sup>



Treatment strategy is based upon individual patient needs and physician discretion.



**Key organizations recommend Firialta to improve CV and renal outcomes<sup>2,3-8</sup>**

ACEi=angiotensin-converting-enzyme inhibitor; ARB=angiotensin receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; MRA=mineralocorticoid receptor antagonist; SGLT2=sodium-glucose cotransporter-2; T2D=type 2 diabetes.

**References:** 1. Blazek O, et al. Am Heart J. 2022;191:1-5. 2. American Diabetes Association<sup>®</sup> Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(suppl1):S191-S202. doi:10.2337/dc23-S011. 3. de Boer IH, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. <https://doi.org/10.2337/dc22-0027>. 4. American Diabetes Association. Addendum 10. Cardiovascular disease and risk management: Standards of medical care in diabetes—2022. Diabetes Care. 2022;45(suppl 1):S144-S174. 5. Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocrine Pract. 2022;(10):923-1049. doi:10.1016/j.jep.2022.08.002. 6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(S5):S1-S127. doi:10.1016/j.kint.2022.06.008. 7. McDonagh TA, et al. Eur Heart J. 2023;00, 1–13. doi:10.1093/eurheartj/ehad195. 8. Marx N, et al. Eur Heart J. 2023;00, 1–98. doi:10.1093/eurheartj/ehad192.

Full prescribing information available upon request.

For Healthcare Professionals Only



Bayer Co. (Malaysia) Sdn Bhd.  
Unit 25-03 & 25-04, Level 25, Imazium, No 8, Jalan SS21/37,  
Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia.  
Website: [www.bayer.com](http://www.bayer.com)

Scan QR code for Abbreviated  
Prescribing Information.



**Jardiance®**  
(empagliflozin)



# MAKE PROTECTION YOUR SUPERPOWER



**JARDIANCE provides triple  
protection in your patients with  
CRM conditions:**



reduced risk  
of CV death  
or kidney disease  
progression<sup>\*1,2</sup>



reduced risk  
of CV death  
or hospitalisation  
for heart failure<sup>\*3,4</sup>



reduced risk  
of CV death<sup>\*5</sup>

**References:** 1. Jardiance® Malaysia Prescribing information. 2. Herrington WG, Staplin N, Wanner C, et al. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med.* 2023;388(2):117-127. (EMPA-KIDNEY results and the publication's Supplementary Appendix.) 3. Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020;383(15):1413-1424. (EMPEROR-Reduced results and the publication's Supplementary Appendix.) 4. Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med.* 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication's Supplementary Appendix.) 5. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication's Supplementary Appendix.)

<sup>\*</sup>In the EMPA-KIDNEY trial, a randomised, parallel-group, double-blind, placebo-controlled study of 6609 patients with CKD, the efficacy and safety of JARDIANCE 10 mg (n=3204) were evaluated vs placebo (n=3305). The primary endpoint in the EMPA-KIDNEY trial was a composite of CV death or progression of kidney disease. Patients treated with JARDIANCE experienced a 28% RRR in this endpoint (HR=0.72; 95% CI: 0.64, 0.82; p<0.001).<sup>2</sup>

<sup>†</sup>In the EMPEROR-Reduced trial, a randomised, double-blind, parallel-group, placebo-controlled study of 3730 patients with HFrEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%). The primary endpoint in the EMPEROR-Reduced trial was a composite of CV death or HFrEF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001). In the EMPEROR-Preserved trial, a randomised, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). Patients were adults with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%). The primary endpoint in the EMPEROR-Preserved trial was a composite of CV death or HFrEF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 21% RRR in this endpoint (HR=0.79; 95% CI: 0.69, 0.90; p<0.001).<sup>1,3</sup>

<sup>\*</sup>The primary composite outcome in the EMPA-REG OUTCOME® trial was 3-point MACE, composed of death from CV causes, nonfatal MI, or nonfatal stroke, as analysed in the pooled JARDIANCE group vs the placebo group. Patients were adults with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke. The 14% RRR in 3-point MACE (HR=0.86; 95% CI: 0.74, 0.99; p<0.001 for noninferiority; p=0.04 for superiority) was driven by a reduction in the risk of CV death (HR=0.82; 95% CI: 0.69, 0.77).<sup>1</sup>

CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; CVD=cardiovascular disease; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFREF=heart failure with reduced ejection fraction; HR=hazard ratio; LVEF=left ventricular ejection fraction; MACE=major adverse cardiovascular events; MI=myocardial infarction; NYHA=New York Heart Association; PAD=peripheral artery disease; RRR=relative risk reduction; T2D=type 2 diabetes.

PC-WH-103569 MAR 2024

For healthcare professionals only.



**Boehringer Ingelheim (Malaysia) Sdn. Bhd.**  
Registration no: 198601000452 (149591-H)  
Suite 15-5 Level 15, Wisma UOA Damansara II,  
No. 6, Jalan Changkat Semantan, Damansara Heights,  
50490 Kuala Lumpur.  
Tel: +603 2092 0088 Fax: +603 2095 2818




Scan QR Code to access  
JARDIANCE latest prescribing  
information





**CAESEVA**  
Sevelamer Carbonate

## Transforming Kidney Health; Balancing Renal Well-Being



**Sevelamer Carbonate**  
**approved in more than 30 countries**  
such as United Kingdom, Spain, Germany, Norway,  
Greece, Switzerland, Netherlands, South Korea & etc



RENAL/EADV-MSN/202405/01



# CREATING A FUTURE WORTH LIVING FOR PATIENTS. WORLDWIDE. EVERYDAY.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. United by a shared purpose of creating a future worth living for chronically and critically ill people, we care for more than 332,000 dialysis patients around the globe.

Their well-being always comes first

Head office: Fresenius Medical Care Malaysia Sdn Bhd  
Second Floor, Axis Technology Centre Lot 13, Jalan 51A/225  
46100 Petaling Jaya, Selangor  
P +603-7952 5888  
F +603-7957 1272

[www.freseniusmedicalcare.my](http://www.freseniusmedicalcare.my)





## MEDICAL DEVICE PRODUCTS

### MISSION

To further innovate superior quality healthcare products to the highest standard and to provide outstanding customer services worldwide.



RENACID® X44 Ca1.25

### VISSION

AIN MEDICARE is committed to providing reliable and quality products and services that consistently meet the satisfaction of health professionals and patients, in compliance with regulatory requirements and best practices. We are continuously committed to improving our operations to excel beyond the quality standard. AIN MEDICARE strongly believes in providing excellent services that exceed customer expectations.



RENACARB® Bb2



RENACARB® C1

**"LIFE SOLUTIONS FOR HEALTH AND HEALING"**

Jalan 6/44, Kawasan Perindustrian Pengkalan Chepa 2, 16100 Kota Bharu, Kelantan, Malaysia.  
[www.ainmedicare.com.my](http://www.ainmedicare.com.my)





# REGPARA®

**is indicated for Secondary Hyperparathyroidism  
in patients undergoing maintenance dialysis\***

Abbreviated Prescribing Information REGPARA® TABLETS 25MG  
Based on Malaysia Package Insert: Kyowa Kirin Malaysia Sdn Bhd. 2020.

PLEASE REFER TO THE FULL PRESCRIBING INFORMATION BEFORE PRESCRIBING.

**Indication:** Regpara® is indicated for secondary hyperparathyroidism in patients undergoing maintenance dialysis.  
**Dosage and administration:** The starting dose for adults is 25 mg of cinacalcet once daily, to be orally administered. With careful management of the patient's serum parathyroid hormone (PTH) and calcium levels, the dose may then be adjusted within a range of 25-75 mg once daily. If no improvement is found in PTH, the dose may be increased up to 100 mg once daily. If dose increase is required, dose should be increased by 25 mg at a time, at intervals of at least 3 weeks.  
**Contraindications:** Patients with a history of hypersensitivity to any of the ingredients in Regpara.

**Warnings and precautions:** Patients with hypocalcaemia; patients with seizure or a history of seizure; patients with hepatic function disorder; patients with gastrointestinal hemorrhage and/or gastrointestinal ulcer or a history of gastrointestinal hemorrhage and/or gastrointestinal ulcer.

**Adverse Reactions:** The major adverse reactions included digestive symptoms such as nausea/ vomiting (124 events, 21.6%), gastric discomfort (107 events, 18.7%), anorexia (56 events, 9.8%) and abdominal distention (34 events, 5.9%), as well as hypocalcaemia/ decreased serum calcium (84 events, 14.7%) and prolonged QT interval (33 events, 5.8%). [Data at the time of approval in Japan]

\*Regpara® Tablets 25 mg Package Insert Revised: Mar 2020

**-DRUG FOR TREATMENT OF SECONDARY  
HYPERPARATHYROIDISM  
(CALCIUM RECEPTOR AGONIST)  
REGPARA® TABLETS 25mg  
<Cinacalcet Hydrochloride>  
THIS MATERIAL IS MEANT FOR HEALTHCARE PROFESSIONALS ONLY.**

**Malaysia Logistic Service Provider  
Apex Pharmacy Marketing Sdn. Bhd.**  
No.2, Jalan SS13/5,  
47500 Subang Jaya, Selangor, Malaysia.  
Tel: +603 5629 3688 Fax: +603 5636 8200

**KYOWA KIRIN**

**Kyowa Kirin Malaysia Sdn. Bhd. (1213183-P)**  
Suite A501, 5th Floor, West Wing, Wisma Consplant 2,  
No. 7, Jalan SS 16/1, 47500 Subang Jaya, Selangor.

MY-REG-23-00001



# ARE YOU OFFERING PNEUMOCOCCAL VACCINATION AT YOUR CLINIC?


► If yes, list your clinic on our pneumococcal vaccination clinic directory!



We will publicise the clinic directory through social media!

**Scan this QR code to get listed.**

\*We will advise the public to call the clinics first to seek appointment & confirm vaccine stock availability.



**Want to increase your patients' awareness of adult & pneumococcal vaccination?**

Get 50 free hard copies of in-clinic educational materials delivered to your clinic.



My Vaccination Journal




Risk Factor Estimator Kit  
Available in ENG, BM & CHI



Scan the QR code to place your order

**Would like to know more about pneumococcal vaccination for adults and its recommendations?**



Download the "Position Paper on Pneumococcal Vaccination for Older Person and High-Risk Adults"



Scan the QR code to download

The Prevent Pneumococcal Pneumonia Campaign is supported by an educational grant from

